- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Cerenome, Inc. (Plus Therapeutics, Inc. until August 3, 2026), was formerly known as Cytori Therapeutics, Inc. In 2017, Cytori Therapeutics announced that it had acquired a nanomedicine platform. In 2019, Cytori Therapeutics announced that it had divested its autologous cell therapy assets to Lorem Vascular of Australia and Seijiro Shirahama of Japan. In 2019, Cytori Therapeutics announced that it had changed its focus and name to Plus Therapeutics. In 2020, Plus Therapeutics announced that it had licensed a novel oncology platform, including multiple radiopharmaceutical assets. Plus Therapeutics announced on July 31, 2026 a rebranding as Cerenome, which took effect on August 3, 2026.